CLAIMS

1. A compound or its pharmaceutically-acceptable salt of a formula (I):



(I)

wherein, A_1 represents a hydrogen atom, a group selected from a substituent group β optionally having 1 or 2 groups selected from a substituent group α, or a phenyl or heteroaryl group, which are optionally having 1 or 2 groups selected from a substituent group γ; j and k each independently indicate 0 or 1; when j is 0, then a formula (III-1):



in the formula (I) represents a double bond, and when j is 1, then the formula (III-1) represents a group of:



(wherein A_2 has the same meaning as A_1); when k is 0, then a formula (III-2):



in the formula (I) represents a double bond, and when k is 1, then the formula (III-2) represents a group of:



(wherein A_3 has the same meaning as A_1); regarding W_1 and W_2, one of W_1 and W_2 is A_4 and the other is E-O-W, or when j is 1, then W_1 may be E-O-W and A_2-C=C-W_2 may together form a benzene ring or a heteroaryl ring having from 1 to 3, the same or different hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom (the benzene ring and the heteroaryl ring may be substituted with a nitro group, a hydroxy group, a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, an alkanoylamino group); E represents a phenyl group optionally having from 1 to 3 groups selected from a substituent group δ, or a 5- or 6-membered monocyclic aromatic heterocyclic group having 1 or more, preferably from 1 to 3, the same or different hetero atoms selected from a group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or represents a condensed-cyclic aromatic heterocyclic group that the monocyclic aromatic heterocyclic group forms together with an aryl group; W represents a formula (II-1):



(II-1)

,

a formula (II-2):



(II-2)

,

or a formula (II-3):



(II-3)

(wherein G_1 and G_2 may be the same or different, each representing a lower alkyl group (the lower alkyl group may be further substituted with a halogen atom) or a cycloalkyl group, or G_1 and G_2 form, together with the nitrogen atom adjacent to G_1 and G_2, a 5- to 8-membered aliphatic hetero-ring (the hetero-ring may have, in the ring, 1 or 2 groups of a lower alkyl group optionally substituted with a halogen atom or a halogen atom) or a bicyclo-ring; m1 indicates an integer of from 2 to 4; m2 and m3 each indicate an integer of from 1 to 3; (CH_2)m1 in the formula (II-1) may be further substituted with a lower alkyl group having from 1 to 3 carbon atoms;

Substituent group α: an amino group, a nitro group, a cyano group, a hydroxy group, a halogen atom, a lower alkylsulfonyl group, a lower alkyl group (the lower alkyl group may be substituted with a halogen atom), a lower cycloalkyl group (the lower cycloalkyl group may be substituted with a halogen atom), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower cycloalkoxy group (the lower cycloalkoxy group may be substituted with a halogen atom), an aryloxy group, an alaryloxy group, an aryl group, a heteroaryl group, a mono-lower alkylcarbamoyl group, a di-lower alkylcarbamoyl group, a lower alkylcarboxamido group, an arylcarboxamido group, a heteroarylcarboxamido group, an alkanoyl group, an alkylthio group;

Substituent group β: an amino group, a lower alkylsulfonyl group, a lower alkyl group, a lower cycloalkyl group, a lower alkoxy group, a lower cycloalkoxy group, the lower alkyl group being optionally substituted with a halogen atom, a lower cycloalkyl group (the cycloalkyl group may be substituted with a halogen atom), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower cycloalkoxy group (the lower cycloalkoxy group may be substituted with a halogen atom), a carbamoyl group, a mono- or di-lower alkylcarbamoyl group;

Substituent group γ: an amino group, a nitro group, a cyano group, a hydroxy group, a lower alkylsulfonyl group, a halogen atom, a lower alkyl group (the lower alkyl group may be substituted with

a halogen atom), a lower cycloalkyl group (the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom or a hydroxy group), a lower cycloalkoxy group (the lower alkyl group may be substituted with a halogen atom), an aryloxy group, an alaryloxy group, an aryl group, a heteroaryl group, a mono-lower alkylcarbamoyl group, a di-lower alkylcarbamoyl group, a lower alkylcarboxamido group, an arylcarboxamido group, a heteroarylcarboxamido group, an alkanoyl group, an alkylthio group, an alkoxycarbonylamino group, an alkylsulfonylamino group, an arylsulfonylamino group, an alkylaminosulfonyl group or an arylaminosulfonyl group;

Substituent group δ: a halogen atom, a nitro group, a lower alkyl group, a halo-lower alkyl group, a hydroxy group, a hydroxy-lower alkyl group, a cyclo-lower alkyl group, a lower alkenyl group, a hydroxyl group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkylamino group, a di-lower alkylamino group, a lower alkylthio group, a carboxyl group, a lower alkanoyl group, a lower alkoxycarbonyl group.

2. The compound or its pharmaceutically-acceptable salt as claimed in claim 1, wherein A_1 is a hydrogen atom, a lower alkyl group (the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group, a phenyl group, a pyridyl group, a carbamoyl group, a mono- or di-lower alkylcarbamoyl group, and A_2, A_3 and A_4 each are independently a hydrogen atom or a lower alkyl group.

3. The compound or its pharmaceutically-acceptable salt as claimed in claim 1 or 2, wherein one of W_1 and W_2 is A_4, and the other is E-O-W; or when j is 1, then W_1 is E-O-W, and A_2-C=C-W_2 together forms a benzene ring or a heteroaryl ring having 1 or 2 nitrogen atoms in the ring.

4. The compound or its pharmaceutically-acceptable salt as claimed in claim 2 or 3, wherein E is a phenyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group or a pyrazinyl group.

5. The compound or its pharmaceutically-acceptable salt as claimed in claim 2 or 3, wherein E is a phenyl group or a pyridyl group.

6. The compound or its pharmaceutically-acceptable salt as claimed in claim 2 or 3, wherein E is a phenyl group.

7. The compound or its pharmaceutically-acceptable salt as claimed in any one of claims 1 to 6, wherein W is the formula (II-1) or (II-3).

8. The compound or its pharmaceutically-acceptable salt as claimed in any one of claims 1 to 3, wherein the formula (I) is the following formula (I-0):



(I-0)

[wherein the symbols have the same meanings as above].

9. The compound or its pharmaceutically-acceptable salt as claimed in any one of claims 1 to 3, wherein the formula (I) is the following formula (I-1):



(I-1)

[wherein the symbols have the same meanings as above].

10. The compound or its pharmaceutically-acceptable salt as claimed in any one of claims 1 to 3, wherein the formula (I) is the following formula (I-2):



(I-2)

11. The compound or its pharmaceutically-acceptable salt as claimed in any one of claims 1 to 3, wherein the formula (I) is the following formula (I-3):



(I-3)

12. The compound or its pharmaceutically-acceptable salt as claimed in any one of claims 1 to 3, wherein the formula (I) is the following formula (I-4):



(I-4)

[wherein the ring A represents a benzene ring or a heteroaryl ring having 1 or 2 nitrogen atoms in the ring (the benzene ring and the heteroaryl ring may be substituted with a nitro group, a hydroxyl group, a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, an alkanoylamino group)].

13. The compound or its pharmaceutically-acceptable salt as claimed in claim 12, wherein the ring A is a benzene ring or a pyridine ring.

14. The compound or its pharmaceutically-acceptable salt as claimed in claim 1, wherein the formula (I) is:

2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,

2-[4-(1-cyclopentyl-piperidin-4-yloxy)phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine trifluoroacetate,

3-methyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,

3-ethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,

7-methyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,

7-(5-methyl-isoxazol-3-yl)-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,

7-phenyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,

3-methyl-7-phenyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,

3-methyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-7-(pyridin-3-yl)-3aH-pyrazolo[1,5-d][1,2,4]triazine,

6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

7-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine,
3-tert-butyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine,
7-methyl-3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-methyl-7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
3,6-dimethyl-7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-methyl-3-phenyl-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
4-(pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazin-6-yl)-phenol,
4-(pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazin-6-yl)-phenol,
3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
3-phenyl-6-[6-(3-piperidin-1-ylpropoxy)-pyridin-3-ylmethoxy]-[1,2,4]triazolo[3,4-a]phthalazine,
3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-3-yl)-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-2-yl)-[1,2,4]triazolo[3,4-a]phthalazine,
3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-trifluoromethyl-[1,2,4]triazolo[3,4-a]phthalazine,

3-tert-butyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-6-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3,6-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,
6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-[1,2,4]triazolo[4,3-b]pyridazine,
7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,6-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[3,4-a]phthalazine,
6-{4-[3-(2,6-dimethylpiperizin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-{4-[3-(2,5-dimethylpyrrolidin-1-yl)propoxy]-phe,
N-methyl-6-[4-(3-piperidin-1-ylpropoxy)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine-3-carboxamide,
3-(piperidin-1-ylcarbonyl)-6-[4-(3-piperidin-1-ylpropoxy)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-methylpiperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

6-[4-{3-[(3S)-3-fluoropyrrolidin-1-yl]propoxy}-phenyl)-[1,2,4]triazolo[4,3-b]pyridazine,
6-{4-[3-(3-methylpiperidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-{4-[3-(4-fluoropiperidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-{4-[3-(3-fluoropiperidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-{3-[(2R)-(2-methylpyrrolidin-1-yl]propoxy)-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
6-[4-{3-[(2S)-(2-methylpyrrolidin-1-yl]propoxy)-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
N,N-dimethyl-6-[4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy)-phenyl}-[1,2,4]triazolo[3,4-a]phthalazine-3-carboxamide,
6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
3-methyl-6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

3-methyl-6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

3-methyl-6-(4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

3-methyl-6-(4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

3-methyl-6-(4-{3-[(2R)-3-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

3-methyl-6-(4-{3-[(2R)-3-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-3-methylpyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-3-methylpyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]-3-methylpyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-[1,2,4]triazolo[3,4-a]phthalazine or

6-{6-[(3S)-3-piperidin-1-ylpropoxy]pyridin-3-yl]-[1,2,4]triazolo[3,4-a]phthalazine.

15. A histamine receptor-H3 antagonist containing, as the active ingredient thereof, a compound of any one of claims 1 to 14.

16. A histamine receptor-H3 inverse-agonist described in any one of claims 1 to 14.

17. A preventive or remedy containing, as the active ingredient thereof, a compound or its pharmaceutically-acceptable salt of any of claims 1 to 14, which is for metabolic system diseases, circulatory system diseases or nervous system diseases.

18. The preventive or remedy as claimed in claim 17, wherein the metabolic system diseases are at least one selected from obesity, diabetes, hormone secretion disorder, hyperlipemia, gout and fatty liver.

19. The preventive or remedy as claimed in claim 17, wherein the circulatory system diseases are at least one selected from stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy and electrolyte metabolism disorder.

20. The preventive or remedy as claimed in claim 17, wherein the nervous system diseases are at least one selected from sleep disorder, diseases accompanied by sleep disorder, bulimia, emotional disorder, epilepsy, delirium, dementia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, recognition disorder, motion disorder, paresthesia, dysosmia, morphine resistance, narcotic dependency, alcoholic dependency and tremor.

21. The preventive or remedy as claimed in claim 17, wherein the nervous system diseases are at least one selected from idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, melancholia, anxiety, schizophrenia.

22. A preventive or remedy for metabolic system diseases, circulatory system diseases or nervous system diseases, which contains, as the active ingredients thereof, the compound or its pharmaceutically-acceptable salt of any one of claims 1 to 14 and an additional drug.